Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667897 | 0.83 | CRACR2A (0.52) | CRACR2AORAI1 | |
| SCHEMBL20080531 | 0.81 | CRACR2A (0.60) | CRACR2A | |
| SCHEMBL1668362 | 0.79 | CRACR2A (0.58) | CRACR2A | |
| SCHEMBL1668357 | 0.79 | CRACR2A (0.58) | CRACR2A | |
| SCHEMBL1670439 | 0.78 | CRACR2A (1.00) | CRACR2A | |
| SCHEMBL1668025 | 0.78 | CRACR2A (0.73) | CRACR2A | |
| SCHEMBL1883613 | 0.78 | CRACR2A (0.77) | CRACR2A | |
| SCHEMBL1882038 | 0.75 | CRACR2A (0.69) | CRACR2AORAI1 | |
| SCHEMBL1668202 | 0.74 | CRACR2A (0.55) | CRACR2AORAI1 | |
| SCHEMBL30096524 | 0.74 | ORAI1 (0.71) | CRACR2AORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2018-08-09 | — | — | US | disclosed |
| EP-2509955-B1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-25 | — | — | EP | disclosed |
| US-9944631-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-17 | — | — | US | disclosed |
| EP-3299361-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8921364-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | Rhizen Phamaceuticals SA (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| EP-2509955-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-05 | — | — | US | disclosed |
| WO-2011042797-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | ICOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105447-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885 |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-20190160046-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-20130310377-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-20150166526-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-20180222898-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | CRACR2A 58/4885ORAI1 1/4885 |
| US-10246450-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | CRACR2A 55/4885ORAI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.